TABRECTA (capmatinib)

TherapyNovartis

TABRECTA (capmatinib) from Novartis is a targeted MET inhibitor used in biomarker-defined lung cancer.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and TABRECTA. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where TABRECTA is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
Non-Small Cell Lung Cancer (NSCLC) Solid Tumor · Lung	MET single nucleotide variants and indels that lead to MET exon 14 skipping		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for TABRECTA.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering TABRECTA for eligible patients.

Test

FoundationOne CDx

Foundation Medicine, Inc.

Method

NGS

Specimen

Tissue (FFPE)

1 approvalView test profile →

Test

FoundationOne Liquid CDx

Foundation Medicine, Inc.

Method

NGS

Specimen

Whole blood

1 approvalView test profile →

This view is scoped to TABRECTA (capmatinib). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.